Contrasting Enfusion (ENFN) & Its Rivals

Enfusion (NYSE:ENFNGet Rating) is one of 420 public companies in the “Prepackaged software” industry, but how does it compare to its rivals? We will compare Enfusion to related businesses based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

50.0% of Enfusion shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Prepackaged software” companies are owned by institutional investors. 40.1% of Enfusion shares are owned by company insiders. Comparatively, 19.2% of shares of all “Prepackaged software” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Enfusion and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Enfusion $111.70 million -$158.32 million -5.36
Enfusion Competitors $1.81 billion $284.34 million -8.44

Enfusion’s rivals have higher revenue and earnings than Enfusion. Enfusion is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Enfusion and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enfusion -213.18% -57.75% -52.51%
Enfusion Competitors -61.68% -73.92% -9.28%

Analyst Recommendations

This is a summary of current ratings and target prices for Enfusion and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enfusion 0 4 2 0 2.33
Enfusion Competitors 1780 11868 25142 562 2.62

Enfusion presently has a consensus price target of $14.50, indicating a potential upside of 14.17%. As a group, “Prepackaged software” companies have a potential upside of 40.68%. Given Enfusion’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Enfusion has less favorable growth aspects than its rivals.


Enfusion rivals beat Enfusion on 9 of the 12 factors compared.

About Enfusion

(Get Rating)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with's FREE daily email newsletter.